Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007
January 28, 2020 08:02 ET | Seelos Therapeutics, Inc.
Delivery of SLS-007 to Utilize an Adeno-Associated Virus (AAV) VectorSLS-007 to Become Seelos’ Second Gene Therapy Program Focused on Parkinson’s  NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Seelos...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005) 
December 04, 2019 08:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Reports Q3 2019 Pipeline Update
November 08, 2019 07:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update. “Seelos continued...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant
October 15, 2019 09:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today announced the addition of Scott Applebaum to its team as lead...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Participate in Upcoming Investor Conference in September
September 04, 2019 09:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Oppenheimer Fall...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering
August 23, 2019 09:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Reports Q2 2019 Pipeline Update
August 01, 2019 09:00 ET | Seelos Therapeutics, Inc.
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, today released its second quarter pipeline update. “We have made...
retro.jpg
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Phospholipase 2G6 (PLA2G6)-Associated Neurodegeneration
November 02, 2017 09:00 ET | Retrotope
LOS ALTOS, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Retrotope announced today that the U.S. Food and Drug Administration’s (FDA’s) Office of Orphan Products Development (OOPD) granted orphan drug...
retro.jpg
Study of Retrotope’s deuterated polyunsaturated fatty acid drugs published in The FEBS Journal
October 30, 2017 09:00 ET | Retrotope
LOS ALTOS, Calif. and TORONTO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Retrotope and collaborators, led by Dr. Brian Bennett of Queen’s University, have published a paper entitled “Deuterium-reinforced...
Neuronascent Appoints New Board Member
April 12, 2017 06:30 ET | Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - April 12, 2017) - Neuronascent, Inc., a neuro-pharmaceutical company developing proprietary therapeutics for Alzheimer's disease, Parkinson's disease, and psychiatric...